Trial Profile

Phase II Study of the Hyper - CVAD Regimen in Combination With Ofatumumab as Frontline Therapy for Patients With CD-20 Positive Acute Lymphoblastic Leukaemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ofatumumab (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Methotrexate; Methotrexate; Rituximab; Vincristine
Indications B-cell leukaemia; Burkitt's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use

Most Recent Events

17 Jun 2021 Results of propensity score analysis in Philadelphia chromosome negative acute lymphoblastic leukemia, published in the Cancer.
16 Apr 2020 Status changed from active, no longer recruiting to completed.
06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com